How overlooked markets, funding blind spots, and embedded bias are defining the next frontier of health innovation
Imagine receiving approval in 2017 for a patent on something as simple as a sponge or a pen, an everyday object whose basic function seems obvious. Yet this is essentially what happened when my patent for a new type of hygiene device for women was approved. The experience revealed something that every operator in health innovation eventually confronts: the most significant market gaps are often the ones that have been hiding in plain sight. For those of us building in women's health, this is not an abstract observation. It is the daily operating reality.
Today, we may finally be reaching a turning point, but it will require founders, investors, and operators to make decisions different from those they have made in the past.
I was born 55 years ago into a society where my father, the man, was the breadwinner, while my mother, the woman, worked part-time and managed all the housework. From the very first moment I entered this world, I was exposed to patterns of gender inequality that became subconsciously ingrained. It was always clear to me that I was not expected to perform or achieve the same accomplishments as my older brother. I grew up like many of my peers, sharing similar patterns of thought and expectations.
As an Israeli, I knew that when I grew up, I would serve in the army, but meaningful roles, pilot, fighter, would be closed to me because of my gender. I also knew I would retire earlier than men. The childhood stories of Snow White and Cinderella created in my mind the dream that one day a perfect, strong prince would take care of the family and me, and we would build together. That has since changed; women in Israel can now serve in almost all roles, but the mental frameworks those expectations created take far longer to rewrite.
It took me many years to recognise some of my own blind spots regarding gender inequality and to gradually remove them one by one. These were things I had taken for granted without realising they did not have to be this way. One such moment occurred when a company called Egal introduced a new toilet-paper-style sanitary pad that solved a long and painful problem shared by menstruators around the world. A relatively simple technological solution, yet it had not existed before. This is a strong example of how gender-focused technology can close gaps that arise directly from anatomical differences, gaps that went unaddressed not because the solution was technically complex, but because the people controlling research priorities and funding did not experience the problem themselves.
As a woman entrepreneur working in women's health for over 20 years, I have experienced firsthand many of the structural blind spots surrounding gender gaps - in funding, in research, in market assumptions. These gaps were partly created by anatomical differences between the sexes, which means health innovation sits at the doorway of closing them. The opportunity is significant. So is the friction.
THE FUNDING GAP IS NOT ONLY A MAN'S PROBLEM
Women often believe that these gaps exist only in men's thinking. In my experience, that is not the case. One of the main factors still holding back women's health innovation is the blind spots in women's own decision-making - our internalised biases about risk, return, and what constitutes a serious investment opportunity.
It is no secret that women invest significantly less than men, and when they do, they tend toward more conservative risk profiles. When we examine how the wealthiest women in the world deploy their resources, we often see a preference for philanthropic causes over early-stage innovation. Many of the funds created specifically to support women, including those offered by organisations such as Pivotal, founded by Melinda Gates, are structured for non-profits and are not accessible to commercial ventures like mine.
This matters because risk capital is what turns early-stage health innovation into workable products. Women's health companies cannot expect male investors to deeply understand problems they do not personally experience; it is only natural that people hesitate to fund problems they do not fully grasp. But significant change will only come when women investors and operators recognise and actively override these blind spots. The frustration is legitimate. The solution requires action, not just acknowledgment.
THE SYSTEMIC RISK HIDING IN THE DATA
Beyond funding, a more systemic risk is emerging that operators cannot afford to ignore. Our mental frameworks are usually shaped in ways that lead women to perceive themselves as less capable and to expect less of their own potential. Artificial intelligence, which is increasingly influential in decision-making across industries, has been shown to contain inherent gender biases. The reason is clear: large language models are trained with vast collections of published text, much of which reflects centuries of gender inequality. As a result, instead of helping to eliminate existing gaps, these systems risk preserving them within our collective digital infrastructure.
This is not a philosophical concern. It is an operational one. AI is now embedded in hiring decisions, medical diagnostics, research prioritisation, and investment screening. If these systems carry embedded gender biases, they will not simply reflect the inequalities society is trying to overcome; they will accelerate them at scale.
A BETTER WORLD FOR EVERYONE
More than forty years ago, humanity walked on the Moon through bold technological innovation. Yet here on Earth, medicine still struggles to properly address conditions such as endometriosis, menopause, fibromyalgia, and many other health challenges influencing millions of women globally. These are not niche concerns. They represent some of the largest addressable gaps within modern healthcare, and some of the most significant commercial opportunities for founders and investors willing to look.
The solutions exist, or can be created. Gender-focused technologies and research have the potential to dramatically improve women's health and close longstanding gaps.
But the market will not self-correct. It requires operators- founders, investors, researchers, and executives, to make deliberate choices about where they direct capital, talent, and attention.
Those who build here first will not only advance women's health. They will have shaped one of the most consequential and underserved markets of the next decade.